S&P Futures
5,909.75 +3.75 (+0.06%) Dow Futures
43,548.00 +30.00 (+0.07%) Nasdaq Futures
20,494.25 +10.75 (+0.05%) Russell 2000 Futures
2,294.60 +3.40 (+0.15%) Crude Oil
69.56 +0.34 (+0.49%) Gold
2,747.00 +17.00 (+0.62%)
CRNX Nov 2024 55.000 call
| Previous Close | 6.30 |
| Open | 6.22 |
| Bid | 4.60 |
| Ask | 7.50 |
| Strike | 55.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 6.22 - 6.22 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 56 |
GuruFocus.comState Street Corp's Strategic Acquisition in Crinetics Pharmaceuticals
On September 30, 2024, State Street Corp made a significant addition to its investment portfolio by acquiring 2,838,484 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX). This transaction, executed at a price of $51.10 per share, marks a notable expansion in State Street Corp's holdings within the biotechnology sector. The addition of these shares has increased the firm's total stake in Crinetics Pharmaceuticals to a substantial 3.60% of its portfolio, reflecting a strategic move to bolster its presence in the biotech industry.
GlobeNewswireCrinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Tuesday, November 12 @ 4:30 p.m. ET Domestic: 1-800-579-2543International: 1-785-424-1789Conference ID: CRNXQ3 Participants can use
